&w=3840&q=100)
LIC inks $1 billion in bond derivatives as hedging gains traction
The move reflects the insurer's growing use of hedging tools as it looks to protect long-term returns amid rising market volatility and falling equity valuations.
What's the latest
According to a Bloomberg report, LIC has entered into FRA contracts with JPMorgan Chase & Co. and Bank of America Corp, locking in future bond yields to guard against declining interest rates.
The $1 billion in FRA deals represents a sharp increase in LIC's derivatives activity, accounting for 38 per cent of the $2.6 billion cleared in India since May.
Numbers game
Share of total FRA trades since May: 38 per cent
LIC asset base: $630 billion
Loss in equity portfolio (Jun 30–Jul 25): ₹46,000 crore
Portfolio value drop: ₹16.10 trillion → ₹15.64 trillion
Equity portfolio value gain since Apr low: ₹1.94 trillion
Nifty 50 index (Jul 25): 24,837
Sensex index (Jul 25): 81,463.09
What it means
LIC's deepening foray into bond hedging marks a significant shift for India's largest institutional investor, indicating that even state-backed entities are now actively mitigating interest rate risk.
As government bond auctions draw stronger demand and financial markets experience higher volatility, large investors like LIC are turning to derivatives to stabilise returns and manage risk exposures.
This also points to increasing sophistication in India's financial risk management practices, especially among long-term asset holders.
Backstory
LIC began exploring bond derivatives in late 2024, initially executing small trades earlier this year. As market uncertainty grew, it gradually expanded its hedging strategy to include FRAs.
Forward rate agreements allow the insurer to lock in interest rates for future bond purchases, with banks assuming the price risk. This hedging mechanism offers a buffer against rate cuts, which can reduce bond yields and impact LIC's long-term income streams.
LIC equity portfolio losses
At the same time, LIC has faced losses in its stock investments this month. As earlier reported by Business Standard, estimates show the market value of LIC's equity portfolio declined by ₹46,000 crore between June 30 and July 25, 2025, as benchmark indices Nifty 50 and BSE Sensex fell 2.6 per cent to 24,837 and 81,463.09, respectively.
LIC's 322-stock portfolio declined from ₹16.10 trillion to ₹15.64 trillion over that period. Still, the portfolio is ₹1.94 trillion higher than it was in early April, when markets hit their lowest point in a year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
15 minutes ago
- Economic Times
Britannia Q1 Results: Cons PAT rises 3% YoY to Rs 521 crore, revenue grows 9%
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .) Subscribe to ET Prime and read the Economic Times ePaper Sensex Today. Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
Mint
15 minutes ago
- Mint
Vertex Falls After FDA Doubts Broad Use of Chronic Pain Drug
(Bloomberg) -- Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to benefit patients after surgery and US regulators said they didn't see a path forward for broad use of its pill in treating a chronic pain condition. Vertex has been trying to diversify beyond its core business of cystic fibrosis treatments. A key part of that strategy has been its new non-opioid pain drug, Journavx, which got US regulatory clearance in January. It was the first new type of painkiller to reach the US market in more than two decades. Shares of Vertex Pharmaceuticals fell as much as 14% in premarket trading on Tuesday. The stock is up 17% since the start of the year through Monday's close. The company is also developing the pill, a safer alternative to addictive opioids, for chronic pain caused by nerve damage. US Food and Drug Administration staff members reviewing a study of the drug said they didn't see a path forward for widespread use in the condition at this time, Vertex said in a statement disclosing its second-quarter earnings results. The drugmaker also has been studying other drugs in its pipeline to see if they have better efficacy than Journavx. The experimental pain drug VX-993 failed in a mid-stage study for treating acute pain, and Vertex halted its development as a standalone therapy for the condition, it said in a separate statement. The setback at the FDA and mid-stage trial failure 'should cause a rethink of the overall opportunity and risk profile for the pain franchise,' RBC Capital Markets analyst Brian Abrahams said in a note. The drugmaker said it would conduct a second trial of Journavx in patients with diabetic peripheral neuropathy, and won't start a final study that was being planned in a different condition. Diabetic peripheral neuropathy is 20% of the neuropathic pain market, Abrahams said. More than 110,000 prescriptions for the medicine have been written and filled for acute pain conditions since it became available in early March, the company said. The novel pain drug VX-993 didn't yield a statistically significant benefit for patients getting bunionectomy surgery, the company said. The failure suggests 'it may be more challenging than some expected to iterate and improve upon' Journavx, Abrahams said in a note. The FDA's stance removes the potential for Vertex to capture the broadest chronic pain market, he said. The company also reported second-quarter revenue and profit that came in ahead of analyst estimates, and reaffirmed its full-year revenue view. Chief Scientific Officer David Altshuler announced his plan to retire on Aug. 1, 2026. Mark Bunnage, the current senior vice president of global research, will take over the role on Feb. 1 as part of a transition plan, the company announced. --With assistance from Subrat Patnaik. (Updates with premarket shares in the third paragraph.) More stories like this are available on
&w=3840&q=100)
Business Standard
15 minutes ago
- Business Standard
Markets fall after Trump's additional tariff threat on Russian crude oil
Indian equity benchmarks declined on Tuesday after US President Donald Trump renewed his threat to impose additional tariffs on India over its oil purchases from Russia. General caution ahead of the Reserve Bank of India's (RBI's) monetary policy decision on Wednesday also weighed on sentiment. The Sensex ended the session at 80,710, down 309 points or 0.4 per cent. The Nifty closed at 24,650, a decline of 73 points or 0.3 per cent. The total market capitalisation of BSE-listed firms fell by ₹83,000 crore to end at ₹448 trillion. Trump on Monday said he would substantially raise tariffs on India to penalise it for importing Russian oil, although he did not specify by how much. His latest announcement follows a 25 per cent tariff on Indian imports announced last week — among the steepest for a major economy. In a social media post, the US President said India was not only buying large quantities of Russian oil but also selling it on the open market for significant profits, disregarding the humanitarian toll of the war in Ukraine. He had earlier given an August 8 deadline for Russia to reach a truce and threatened secondary sanctions on countries continuing to purchase Russian energy. Ukraine's allies argue such purchases support the Russian economy and ease pressure on the government to end its military campaign, now entering its fourth year. India's external affairs ministry responded by stating that the country began purchasing Russian oil only after traditional suppliers diverted shipments to Europe following the onset of the war. The ministry said the US had, at the time, encouraged such imports. It called the targeting 'unjustified and unreasonable' and asserted that India would take all necessary steps to safeguard its national interests and economic security. Relations between the two countries have been strained by the tariff imposition following months of negotiations. India has also taken exception to Trump's claim that he helped resolve its conflict with Pakistan earlier this year. Looking ahead, trade negotiations with the US and the outcome of the RBI policy meeting will influence the near-term market trajectory. 'Investors are now awaiting the upcoming RBI policy decision, where the market has marginal expectations of a rate cut in the near term. Currently, the preferences of investors are for domestic consumption-driven stocks and sectors holding limited volatility to external factors,' said Vinod Nair, head of research at Geojit Financial Services. Market breadth was weak, with 2,371 stocks declining and 1,672 advancing. ICICI Bank, down 1.3 per cent, was the biggest contributor to the Sensex's fall, followed by Reliance Industries, which slipped 1.4 per cent. 'The near-term downtrend of Nifty remains intact, and the market is expected to slide towards the 24,500–24,400 levels in the next few sessions. However, tomorrow's RBI mid-quarter policy outcome is expected to provide clear direction. Immediate resistance is placed at the 24,800 level,' said Nagaraj Shetti, senior technical research analyst at HDFC Securities.
